Pediatrix Medical Group, Inc. MD R2K
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. It also provides other pediatric subspecialty care, including pediatric intensivists, pediatric hospitalists, and pediatric surgeons; support services in other areas of hospitals comprising pediatric emergency room, labor and delivery area, and nursery and pediatric departments; a newborn hearing screening program. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Strong return on equity of 20.9%.
- Profit CAGR of 35.6% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -1.0% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MD Pediatrix Medical Group, Inc. R2K | 21.54 | 10.46 | $1.77B | - | 14.12% | 20.89% | -0.99% | 35.60% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 835.60M | 842.94M | 868.95M | 910.82M | 852.63M | 864.99M | 848.76M | 888.44M | 427.09M | 439.15M | 454.91M | 458.60M | 441.25M | 415.44M | 460.63M | 416.63M | 446.75M | 472.96M | 492.95M | 482.23M | 486.03M | 489.92M | 491.01M | 500.58M | 506.61M | 495.10M | 504.30M | - | - | 458.36M | 468.84M | 492.88M | 493.77M | 476.20M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 355.72M | 344.12M | 352.53M | 367.79M | 363.23M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 102.64M | 124.73M | 140.35M | 125.98M | 112.96M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 63.94M | 61.03M | 66.34M | 71.31M | 66.39M |
| Operating Income | 151.13M | 150.96M | 124.23M | 147.78M | 156.89M | 142.78M | 106.04M | 121.90M | 126.43M | 125.70M | 99.66M | 122.39M | 104.21M | 105.55M | 39.99M | 43.05M | 48.57M | 40.14M | 10.80M | 34.56M | 20.46M | 32.30M | 26.10M | 50.02M | 58.79M | 39.11M | 50.16M | 47.39M | 30.04M | 48.50M | 40.27M | 15.89M | -157.72M | - | - | 38.71M | 63.70M | 74.00M | 54.67M | 46.58M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.58M | 69.41M | 102.27M | 59.97M | 53.23M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.15M | 9.13M | 8.94M | 8.74M | 8.27M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.09M | 54.97M | 87.78M | 45.59M | 38.84M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.35M | 15.71M | 16.07M | 11.91M | 9.27M |
| Net Income | 90.78M | 92.70M | 67.90M | 82.43M | 96.51M | 78.08M | 54.69M | 63.70M | 65.88M | 136.10M | 63.43M | 79.41M | 65.58M | 60.21M | -242.87M | -8.24M | -1.26B | 9.33M | -18.71M | -672.44M | -41.04M | -64.30M | 17.64M | 35.01M | 30.80M | -21.19M | 27.14M | 30.73M | 14.21M | 28.28M | 21.39M | 4.04M | -153.03M | - | - | 20.74M | 39.26M | 71.71M | 33.68M | 29.57M |
| Diluted EPS | 0.97 | 0.99 | 0.73 | 0.89 | 1.04 | 0.84 | 0.59 | 0.69 | 0.71 | 1.46 | 0.68 | 0.85 | 0.72 | 0.68 | -2.81 | -0.10 | -15.15 | 0.11 | -0.22 | -8.03 | -0.49 | -0.76 | 0.21 | 0.41 | 0.36 | -0.25 | 0.32 | 0.37 | 0.17 | 0.34 | 0.26 | 0.05 | -1.84 | - | 0.35 | 0.24 | 0.46 | 0.84 | - | 0.36 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 3.18B | 3.25B | 1.72B | 1.78B | 1.73B | - | 1.97B | 1.99B | 2.01B | 1.91B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.50B | 1.57B | 1.56B | 1.42B |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 467.03M | 421.56M | 454.34M | 493.70M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 267.03M | 263.71M | 270.66M | 262.62M |
| Operating Income | 242.03M | 288.93M | 312.91M | 355.39M | 389.52M | 452.13M | 513.00M | 557.87M | 571.69M | 454.89M | 248.39M | 171.76M | 98.13M | - | 200.00M | 157.85M | 183.68M | 231.09M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 156.70M | 29.89M | -28.37M | 274.22M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.70M | 42.08M | 40.74M | 35.97M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 81.37M | -48.36M | -101.34M | 216.43M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.81M | 12.05M | -2.27M | 51.04M |
| Net Income | 169.20M | 175.80M | 202.69M | 218.00M | 240.91M | 280.52M | 317.28M | 336.32M | 324.91M | 320.37M | 268.63M | -1.50B | -796.49M | - | 66.33M | -60.41M | -99.07M | 165.39M |
| Diluted EPS | 3.59 | 3.78 | 4.26 | 2.23 | 2.42 | 2.78 | 3.18 | 3.58 | 3.49 | 3.45 | 2.93 | -17.83 | -9.55 | - | 0.79 | -0.73 | -1.19 | 1.94 |
Compounded Sales Growth
| 5 Years: | -0.99% |
| 1 Year: | 3.90% |
Compounded Profit Growth
| 5 Years: | 35.60% |
| 1 Year: | 50.00% |
Stock Price Performance
| 1 Year: | +52.23% |
| 6 Months: | -12.62% |
| 3 Months: | +8.51% |
| 1 Month: | -3.45% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.69B | 2.04B | 2.27B | 2.75B | 3.01B | 3.61B | 4.55B | 5.34B | 5.87B | 5.94B | 4.15B | 3.35B | - | 2.35B | 2.22B | 2.15B | 2.25B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 427.99M | 483.45M | 639.61M | 763.51M |
| Cash & Equivalents | 102.84M | 14.35M | 26.50M | 26.25M | 18.60M | 21.28M | 31.14M | 47.93M | 51.57M | 55.70M | 40.45M | 40.77M | 107.87M | 1.12B | - | 9.82M | 73.26M | 229.94M | 375.24M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 296.79M | 272.31M | 259.99M | 229.66M |
| Total Liabilities | - | - | 499.25M | 590.19M | 541.63M | 714.97M | 665.73M | 1.34B | 2.11B | 2.58B | 2.80B | 2.85B | 2.65B | 2.60B | - | 1.46B | 1.37B | 1.39B | 1.38B |
| Current Liabilities | - | - | 346.70M | 221.06M | 254.30M | 268.34M | 326.79M | 416.27M | 428.77M | 448.95M | 531.42M | 502.76M | 541.82M | 444.33M | - | 426.98M | 388.95M | 434.11M | 458.91M |
| Long Term Debt | - | - | - | - | - | - | 27.00M | 557.45M | 1.26B | 1.68B | - | - | - | - | - | 627.65M | 611.59M | 593.57M | 568.95M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 717.08M | 701.65M | 662.31M | 634.62M |
| Total Equity | 959.05M | 965.14M | 1.19B | 1.45B | 1.73B | 2.04B | 2.34B | 2.26B | 2.44B | 2.76B | 3.07B | 3.09B | 1.50B | 747.49M | - | 891.63M | 849.06M | 764.94M | 865.85M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 82.95M | 84.02M | 85.87M | 82.98M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 181.39M | 241.37M | 240.56M | 270.67M | 324.91M | 405.40M | - | - | 443.78M | 511.38M | 313.71M | 357.71M | 204.62M | - | 166.94M | 137.32M | 206.57M | 271.09M |
| Investing Cash Flow | -222.90M | -163.13M | -361.61M | -190.57M | -460.55M | -263.49M | - | - | -821.22M | -576.61M | -142.77M | 102.45M | 815.51M | - | -56.95M | -48.18M | -35.41M | -18.30M |
| Financing Cash Flow | -46.97M | -66.08M | 120.80M | -87.75M | 138.33M | -132.05M | - | - | 381.56M | 89.74M | -170.61M | -393.07M | -4.16M | - | -487.55M | -25.71M | -14.48M | -107.49M |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -29.71M | -33.33M | -22.02M | -18.46M |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 137.23M | 104.00M | 184.55M | 252.63M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -377.57M | 63.43M | 156.68M | 145.30M |
| Share Buybacks | 200.00M | - | - | - | - | 51.86M | 488.43M | 235.05M | 61.83M | 70.19M | 302.16M | 145.28M | 8.49M | 4.72M | 88.51M | 919.00K | 1.70M | 86.68M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.7% | 21.1% | 22.6% | 25.8% |
| Operating Margin % | - | - | - | - | - | - | - | - | 18.0% | 14.0% | 14.4% | 9.7% | 5.7% | - | 10.1% | 7.9% | 9.1% | 12.1% |
| Net Margin % | - | - | - | - | - | - | - | - | 10.2% | 9.8% | 15.6% | -84.2% | -45.9% | - | 3.4% | -3.0% | -4.9% | 8.6% |
| ROE % | 17.5% | 14.8% | 14.0% | 12.6% | 11.8% | 12.0% | 14.0% | 13.8% | 11.8% | 10.4% | 8.7% | -99.9% | -106.6% | - | 7.4% | -7.1% | -13.0% | 19.1% |
| ROCE % | - | 21.5% | 17.2% | 17.6% | 15.7% | 16.9% | 16.1% | 13.5% | 11.7% | 8.5% | 4.6% | 4.8% | 3.4% | - | 10.4% | 8.6% | 10.7% | 12.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 16.53% | 13.57M | $292.39M |
| 2 | Vanguard Portfolio Management LLC | 7.49% | 6.15M | $132.56M |
| 3 | American Century Companies Inc | 4.78% | 3.93M | $84.55M |
| 4 | Dimensional Fund Advisors LP | 4.70% | 3.86M | $83.08M |
| 5 | Victory Capital Management Inc. | 4.68% | 3.84M | $82.76M |
| 6 | Vanguard Capital Management LLC | 4.45% | 3.66M | $78.76M |
| 7 | State Street Corporation | 4.11% | 3.38M | $72.77M |
| 8 | FMR, LLC | 2.76% | 2.27M | $48.84M |
| 9 | Geode Capital Management, LLC | 2.66% | 2.19M | $47.13M |
| 10 | Wasatch Advisors LP | 2.50% | 2.05M | $44.17M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MD